Goal Concordant Care Learning Laboratory
Launched by DUKE UNIVERSITY · May 26, 2023
Trial Information
Current as of October 17, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This study in adults who are Duke Health patients is testing whether giving doctors and other providers feedback about how they talk with patients about goals of care can improve communication in advanced illness (for people with cancer, heart failure, COPD, or dementia). Researchers will try several strategies, including triggering conversations and giving providers feedback on how those conversations are going. Participants are randomly assigned to either receive this provider feedback or to usual care. The study aims to enroll about 5,000 people and is not testing a drug or device.
If you or a family member participate, you’ll be part of the Duke Health patient group (age 18 or older). There are no listed exclusions beyond not being a healthy volunteer. The intervention targets providers, not a specific patient treatment, so you may or may not notice changes in conversations about goals of care. The main outcomes look at how often and how close to death these goals-of-care conversations happen, over roughly two years. The trial does not share individual participant data, and it is currently enrolling by invitation at Duke Health in Durham, NC, with completion expected in 2026.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Duke Health patient
- Exclusion Criteria:
- • None
About Duke University
Duke University, a leading academic and research institution located in Durham, North Carolina, is renowned for its commitment to advancing healthcare through innovative clinical research. With a strong emphasis on interdisciplinary collaboration, Duke conducts a wide array of clinical trials aimed at developing cutting-edge therapies and improving patient outcomes across various medical fields. The university's Clinical Research Institute provides comprehensive support for trial design, implementation, and regulatory compliance, ensuring that all research adheres to the highest ethical and scientific standards. Duke’s dedication to translating research findings into effective clinical practices underscores its role as a pivotal contributor to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Durham, North Carolina, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported